贝伐单抗、卡培他滨及中药维持治疗mCRC的疗效与不良反应评价  

Curative Effects of Bevacizumab, Capecitabine Combined with Herbs in the Maintenance Treatment for mCRC and Evaluation of Adverse Reaction

作　　者：孙海凤 廉娟雯[3] 郭亚焕 赵征 雷宝霞[1] 陈文娟 SUN Haifeng;LIAN Juanwen;GUO Yahuan;ZHAO Zheng;LEI Baoxia;CHEN Wenjuan(Shaanxi Provincial Cancer Hospital,Xi′an 710061,China;Xi′an Jiaotong University Health Science Center;Xi′an Chest Hospital)

机构地区：[1]陕西省肿瘤医院,陕西西安710061 [2]西安交通大学医学部 [3]西安市胸科医院

出　　处：《西部中医药》2019年第11期53-56,共4页Western Journal of Traditional Chinese Medicine

基　　金：陕西省自然科学基础研究计划一般项目（面上）(编号2018JM7025);陕西省肿瘤医院科研基金（编号sxzl-2017-009A）

摘　　要：目的:探讨贝伐单抗、卡培他滨及华蟾素、养正消积胶囊在转移性结直肠癌(metastatic colorectal cancer,mCRC)维持治疗中的疗效与不良反应。方法:将Ⅳ期不可转化切除的结直肠癌(colorectal cancer,CRC)患者80例随机分为2组,研究组采用BEV联合CAP方案维持治疗,对照组采用华蟾素联合养正消积胶囊维持治疗。每隔9周复查疗效,治疗1年后比较2组近期疗效、生活质量及不良反应。结果:研究组部分缓解16例,客观缓解率和疾病控制率分别为40.0%和87.5%,无病进展生存期延长至9.8月,对照组部分缓解3例,客观缓解率和疾病控制率分别为7.5%和52.5%,无病进展生存期延长至7.7月,2组比较差异有统计学意义(P<0.05)。研究组患者血液学毒性、消化道反应、蛋白尿、高血压及手足综合征发生率高于对照组(P<0.05),但上述不良反应可控;对照组仅有轻微腹泻。结论:在mCRC的维持治疗中,BEV+CAP方案安全有效,为患者带来了临床生存获益,而华蟾素与养正消积胶囊的联合应用同样能提高患者生活质量,延长生存期,且不良反应少。Objective:To discuss clinical effects of bevacizumab(BEV),capecitabine(CAP)combined with cinobufotalin capsules and Yangzheng Xiaoji capsules in the maintenance treatment for metastatic colorectal cancer(mCRC)and adverse reaction.Methods:Eighty patients with CRC atⅣstage which can not be removed or transferred were randomly allocated to two groups,the study group adopted maintenance treatment of BEV+CAP regimen,and the control group maintenance treatment of cinobufotalin joined with Yangzheng Xiaoji capsules.Clinical effects were observed every nine weeks,to compare short-term effects,quality of life and adverse reaction between both groups after treating for one year.Results:There were 16 cases with partial response(PR)in the study group,objective remission rate and disease control rate were 40.0%and 87.5%respectively,progression-free survival(PFS)extended to 9.8 months,three cases with PR in the control group,objective remission rate and disease control rate were 7.5%and 52.5%respectively,survival PFS extended to 7.7 months,and the difference had statistical meaning between both groups(P<0.05).Hematological toxicity,digestive tract reaction,albuminuria,hypertension and hand-foot syndrome of the patients in the study group were in higher than these of the control group(P<0.05),and the above adverse reaction were under control,and slight diarrhea happened in the control group.Conclusion:Among maintenance treatment for mCRC,BEV+CAP regimen are safe and effective,it could bring clinical survival benefits for the patients,the combination of cinobufotalin capsules and Yangzheng Xiaoji capsules could lift quality of life of the patients and prolong PFS with minor adverse reaction.

关 键 词：转移性结直肠癌 贝伐单抗 卡培他滨 华蟾素胶囊 养正消积胶囊 维持治疗 生存期 

分 类 号：R735[医药卫生—肿瘤]